| 000 | 00914 a2200277 4500 | ||
|---|---|---|---|
| 005 | 20250510205751.0 | ||
| 264 | 0 | _c19750807 | |
| 008 | 197508s 0 0 eng d | ||
| 022 | _a0140-6736 | ||
| 024 | 7 |
_a10.1016/s0140-6736(75)92056-5 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aLesser, E | |
| 245 | 0 | 0 |
_aLetter: Postscript to thalidomide. _h[electronic resource] |
| 260 |
_bLancet (London, England) _cApr 1975 |
||
| 300 |
_a985 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article | ||
| 650 | 0 | 4 |
_aAbnormalities, Drug-Induced _xetiology |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 |
_aFetus _xdrug effects |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aMaternal-Fetal Exchange |
| 650 | 0 | 4 | _aPregnancy |
| 650 | 0 | 4 |
_aThalidomide _xadverse effects |
| 773 | 0 |
_tLancet (London, England) _gvol. 1 _gno. 7913 _gp. 985 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1016/s0140-6736(75)92056-5 _zAvailable from publisher's website |
| 999 |
_c47081 _d47081 |
||